Thursday, March 14, 2024 12:53:22 PM
IMO the company says whatever they need to say to satisfy their short term goals of either:
inducing retail buying so they can meet the demand of commons being sold which creates liquidity for shareholders to buy Cs
or
making excuses for lack of progress
Still waiting on the barrage of media releases to get the NWBO and DCVAX name out there to boost exposure. Many of us were also expecting to hear about actual developments on partnerships. Now they are too busy to pursue which is an absolute joke. Even if we took a "bad" deal 2-3 years ago we likely would have been better off than continuing to dilute at these levels. Almost 400million shares increase in OS going back to 2021. Somebody is benefiting for this death by 1,000 papercuts and it isn't retail NWBO shareholders.
inducing retail buying so they can meet the demand of commons being sold which creates liquidity for shareholders to buy Cs
or
making excuses for lack of progress
Still waiting on the barrage of media releases to get the NWBO and DCVAX name out there to boost exposure. Many of us were also expecting to hear about actual developments on partnerships. Now they are too busy to pursue which is an absolute joke. Even if we took a "bad" deal 2-3 years ago we likely would have been better off than continuing to dilute at these levels. Almost 400million shares increase in OS going back to 2021. Somebody is benefiting for this death by 1,000 papercuts and it isn't retail NWBO shareholders.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
